Morpholinos and PNAs compared

Letters in Peptide Science

Volumn 10, Issue 3-4, 2003, Pages 215-236

  Summerton, James E ^a  

^a Philomath or 97370 USA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; MORPHOLINE DERIVATIVE; PEPTIDE NUCLEIC ACID; RNA;

BINDING AFFINITY; DNA BINDING; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE SEQUENCE; GENE TARGETING; HUMAN; INTERMETHOD COMPARISON; NONHUMAN; NUCLEIC ACID PROBE; REVIEW; RNA BINDING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS;

EID: 11144290145     PISSN: 09295666     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02484560     Document Type: Review

References (85)

1. Liam, G. and Nielsen, P.E. Progress in developing PNA as a gene-targeted drug. Antisense Nucl. Acid Drug Dev., 7 (1997) 431-437.
2. Nielsen, P. and Egholm, M. (Eds.) Peptide Nucleic Acids. Norfolk: Horizon Scientific Press (1999).
3. Summerton, J. and Weller, D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7 (1997) 187-195.
4. Summerton, J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta, 1489 (1999) 141-158.
5. Summerton, J. (1990) Polynucleotide assay reagent and method. Canadian Patent; 1, 268, 404. Summerton J, Weller D. (1993). Uncharged Morpholino-based polymers having phosphorous containing chiral intersubunit linkages. US Patent; 5, 185, 444.
6. Summerton, J. (1990) Polynucleotide assay reagent and method. Canadian Patent; 1, 268, 404. Summerton J, Weller D. (1993). Uncharged Morpholino-based polymers having phosphorous containing chiral intersubunit linkages. US Patent; 5, 185, 444.
7. Website: www.gene-tools.com
8. Knudsen, H. and Nielsen, P.E. Antisense properties of duplex and triplex forming PNA. Nucl. Acids Res., 24 (1996) 494-500.
9. Milner, N., Mir, K. and Southern, E. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol., 15 (1997) 537-541.
10. Ho, S., Bao, Y., Lesher, T., Malhotra, R., Ma, L., Fluharty, S. and Sakai R. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16(1998)59.
11. Ekker, S. Morphants: a new systematic vertebrate functional genomics approach. Yeast, 17 (2000) 302-306.
12. Koch, T. PNA oligomer synthesis by BOC chemistry. In: P. Neilsen and M. Egholm (Eds.), Peptide Nucleic Acids. Norfolk: Horizon Scientific Press (1999) 21-37.
13. Casale, R., Jensen, I.S. and Egholm, M. Synthesis of PNA oligomers by Fmoc Chemistry. In: P. Neilsen and M. Egholm (Eds.), Peptide Nucleic Acids. Norfolk: Horizon Scientific Press (1999) 39-50.
14. Uhlmann, E., Greinerm B. and Breipohl, G. PNA/DNA chimeras. In: P. Neilsen and M. Egholm (Eds.), Peptide Nucleic Acids. Norfolk: Horizon Scientific Press (1999) 51-70.
15. Stein, C.A. and Cohen, J.S. Phosphorothioate oligodeoxynucleotide analogues. In: J. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Boca Raton: CRC Press (1989) 97-117.
16. Demidov, V., Potaman, V.N., Frank-Kamenetskii, M.D., Buchardt, O., Egholm, M. and Nielsen, P.E. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol., 48 (1994) 1309-1313.
17. Hudziak, R.M., Barofsky, E., Barofsky, D.E., Weller, D.L., Huang, S.B. and Weller, D.D. Resistance of Morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucl. Acid Drug Dev., 6 (1996) 267-272.
18. Nutt, S.L., Bronchain, O.J., Hartley, K.O. and Amaya, E. Comparison of Morpholino based translational inhibition during the development of Xenopus laevis and Xenopus tropicalis. Genesis, 30 (2001) 110-113.
19. Larsen, H.J. and Nielsen, P.E. Characterization of PNA-dsDNA strand displacement complexes. In: P. Neilsen and M. Egholm (Eds.), Peptide Nucleic Acids. Norfolk: Horizon Scientific Press (1999) 221-240.
20. Hanvey, J.C., Peffer, N.J., Bisi, J.E., Thomson, S.A., Cadilla, R., Josey, J.A., Ricca, D.J., Hassman, C.F., Bonham, M.A. and Au, K.G. et al. Antisense and antigene properties of peptide nucleic acids. Science, 258 (1992) 1481-1485.
21. Selecting sequences for Morpholinos, targeting guidelines: http://www.gene-tools.com/Ordering/Ordering1/ body_ordering1.HTML
22. Selecting sequences for PNAs, targeting guidelines: http://www. appliedbiosystems.com/support/seqguide.cfm
23. Miller, P. Non-ionic antisense oligonucleotides: Oligonucleotide alkylphosphotriesters. In: J. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Boca Raton: CRC Press (1989) 82-85.
24. Miller, P. Non-ionic antisense oligonucleotides: Oligonucleotide methylphosphonates. In: J. Cohen (Ed.) Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Boca Raton: CRC Press (1989) 85-92.
25. Stirchak, E., Summerton, J. and Weller, D. Uncharged stereoregular nucleic acid analogues. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages. J. Org. Chem., 52 (1987) 4202-4206.
26. Stirchak, E., Summerton, J. and Weller, D. Uncharged stereoregular nucleic acid analogues. 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucl. Acids Res., 17 (1989) 6129-6141.
27. Gildea, B.D., Casey, S., MacNeill, J., Perry-O'Keefe, H., Sørensen, D and Coull, J.M. Tetrah. Lett., 39 (1998) 7255.
28. Kang, H., Chou, P., Johnson, C., Weller, D., Huang, S, and Summerton, J. Stacking interactions of ApA analogues with modified backbones. Biopolymers, 32 (1992) 1351-1363.
29. Genesis, 30 (2001) 3: Entire issue.
30. Summerton, J., Stein, D., Huang, S., Matthews, P., Weller, D. and Partridge, M. Morpholino and Phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antis. Nucl. Acids Drug Dev., 7 (1997) 63-70.
31. Venter, J.C. et al. The sequence of the human genome. Science, 291 (2001) 1304-1351.
32. Stein, D., Foster, E., Huang, S.B., Weller, D. and Summerton, J. A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and Phosphorothioate DNA. Antis. Nucl. Acids Drug Dev., 7 (1997) 151-157.
33. Summerton, J., Stein, D., Huang, S.B., Matthews, P., Weller, D. and Partridge, M. Morpholino and Phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antis. Nucl. Acids Drug Dev., 7 (1997) 63-70.
34. Akhtar, S., Basu, S., Wickstrom, E. and Juliano, R. Interaction of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucl. Acids Res., 19 (1991) 5551-5559.
35. Akhtar, S. and Juliano, R. Adsorption and efflux characteristics of modified oligodeoxynucleotides from liposomes. Proc. Am. Assoc. Cancer Res. 32 (1991) 333.
36. Neckers, L. Cellular internalization of oligodeoxynucleotides. In: S. Crooke and B. Lebleu B. (Eds.), Antisense Research and Applications. Boca Raton: CRC Press (1993) 451-460.
37. Simmons, C.G., Pitts, A.E., Mayfield, L.D., Shay, J.W. and Corey, D.R. Synthesis and membrane permeability of PNA-peptide conjugates. Bioorg. Med. Chem. Lett. 7 (1997) 3001.
38. Pooga, M., Soomets, U., Hällbrink, M., Valkna, A., Saar, K., Rezaei, K., Kahl, U., Hao, J.X., Xu, X.J., Weisenfeld-Hallin, Z., Hökfelt, T., Bartfai, T. and Langel, Ü. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol., 16 (1998) 857-861.
39. Tyler, B.M., McCormick, D.J., Hoshall, C.V., Douglas, C.L., Jansen, K, Lacy, B.W., Cusack, B. and Richelson, E. Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett., 421 (1998) 280-284.
40. Pardridge, W.M., Boado, R.J. and Kang, Y.S. Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci, 92 (1995) 5592-5596.
41. Aldrain-Herrada, G., Desarménien, M.G., Orcel, H., Boissin-Agasse, L., Méry, J., Brugidou, J. and Rabie, A. A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucl. Acids Res., 26 (1998) 4910-4916.
42. Basu, S. and Wickstrom, E. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconj. Chem., 8 (1997) 481-188.
43. Good, L. and Nielsen, P.E. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat. Biotechnol., 16 (1998) 355-358.
44. Faruqi, A.F., Egholm, M. and Glazer, P.M. Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells. Proc. Natl. Acad. Sci. USA, 95 (1998) 1398-1403.
45. Partridge, M., Vincent, A., Matthews, P., Puma, J., Stein, D. and Summerton, J. A simple method for delivering Morpholino antisense oligos in to the cytoplasm of cells. Antis. Nucl. Acids Drug Dev., 6 (1996) 169-175.
46. Morcos, P.A. Gene switching: analyzing a broad range of mutations using steric block antisense oligonucleotides. Meth. Enzymol., 313 (1999) 174-189.
47. Morcos, P.A. Achieving efficient delivery of Morpholino oligos in cultured cells. Genesis, 30 (2001) 94-102.
48. Monia, B., Johnston, J., Geiger, T., Muller, M. and Fabbro, D. Antitumor activity of a Phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2 (1996) 668-675.
49. Monia, B., Sasmor, H., Johnston, J., Freier, S., Lesnik, E., Muller, M., Geiger, T., Altmann, K., Moser, H. and Fabbro, D. Sequence-specific antitumor activity of a Phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA, 93 (1996) 15481-15484.
50. Baker, B.F. and Monia, B.P. Novel mechanisms for antisense-mediated regulation of gene expression. Biochem. Biophys. Acta, 1489 (1999) 3-18.
51. Quote from Stein, C. and Krieg, A., Non-antisense effects of oligodeoxynucleotides. In: C. Lichtenstein C. and Nellen, W. (Eds.) Antisense Technology. Oxford: IRL Press, 1997: 260. '... non-antisense effects of PS oligos are also pointed out by a close examination of the oligo ISIS 2922, an 'antisense' oligo with remarkably potent antiviral effects against cytomegalovirus (CMV). ISIS 2922 is reported to have encouraging in vivo efficacy in early clinical trials against CMV retinitis. The sequence of this oligo is quite interesting because it has two atypical CpG motifs: there is a GCG at both the extreme 5′ and 3′ ends (79). Although not fully recognized at the time, published studies on ISIS 2922 demonstrate that its antiviral effect cannot be due to 'antisense' since internal mismatch control oligos lost very little antiviral activity despite a severe drop in the Tm. On the other hand, deletion of a single base from one of the CpG motifs caused a 40% drop in antiviral efficacy, and deletion of a single base from both of the CpG motifs abolished antiviral effect despite little change in the Tm for hybridization to the supposed mRNA target (79)'.
52. Kipshidze, N., Moses, J., Shankar, L.R. and Leon, M. Perspectives on antisense therapy for the prevention of restenosis. Curr. Opin. Mol. Ther., 3 (2001) 265-277.
53. Kipshidze, N., Keane, E., Stein, D., Chawla, P., Skrinska, V., Shandar, L.R., Komorowski, R., Haudenschild, C., Leon, M., Keelan, M.H., Moses, J. and Iversen, P. Local delivery of antisense phosphorodiamidate morpholino oligomer: Resten-NG inhibits myointimal hyperplasia following balloon angioplasty. In: F. Navarro-Lopez (Ed.), XXIst Congress of the European Society of Cardiology. Italy: Monduzzi Editore (1999) 463-167.
54. Farrell, C., Bready, J., Saufman, S., Quian, Y. and Burgess, T. The uptake and distribution of Phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antis. Res. Dev., 5 (1995) 175-183.
55. Kimmel, C.B. and Law, R.D. Cell lineage of zebrafish blastomeres. I. Cleavage pattern and cytoplasmic bridges between cells. Dev. Biol., 108 (1985) 78-85.
56. Kimmel, C.B. and Law, R.D. Cell lineage of zebrafish blastomeres. II. Formation of the yolk syncytial layer. Dev. Biol., 108 (1985) 86-93.
57. Stein, C. and Krieg, A. Non-antisense effects of oligodeoxy-nucleotides. In: C. Lichtenstein and W. Nellen (Eds.) Antisense Technology. Oxford: IRL Press (1997) 241-264.
58. Stein, C. Does antisense exist? Nat. Med., 1 (1995) 1119-1121.
59. Norton, J.C., Piatyszek, M.A., Wright, W.E., Shay, J.W. and Corey, D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol., 14 (1996) 615-619.
60. Hamilton, S.E., Pitts, A.E., Katipally, R.R., Jia, X., Rutter, J.P., Davies, B.A., Shay, J.W., Wright, W.E. and Corey, D.R. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry, 36 (1997) 11873-11880.
61. Good, L., Awasthi, S.K., Dryselius, R., Larsson, O. and Nielson, P.E. Bactericidal antisense effects of peptide-PNA conjugates. Nat. Biotechnol., 19 (2001) 360-364.
62. Tyler, B.M., McCormick, D.J., Hoshall, C.V., Douglas, C.L., Jansen, K., Lacy, B.W., Cusack, B. and Richelson, E. Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett., 421 (1998) 280-284.
63. Rusckowski, M., Qu, T., Chang, F. and Hnatowich, D.J. Pretargeting using peptide nucleic acid. Cancer, 80 (1997) (12 suppl) 2699-2705.
64. Thisted, M., Just, T., Pluzek, K.I., Hyldig-Nielsen, J.J., Nielsen, K.V., Mollerup, T.A., Stender, H., Rasmussen, O.F., Adelhorst, K. and Godtfredsen, S.E. Application of peptide nucleic acid probes for in situ hybridization. In: P. Nielsen and M. Egholm (Eds.) Peptide Nucleic Acids: Protocols and Applications. Wymondham: Horizon Scientific Press (1999) 99-118.
65. Matysiak, S., Würtz, S., Hauser, N.C., Gausepohl, H. and Hoheisel, J.D. PNA-arrays for nucleic acid detection. In: P. Nielsen and M. Egholm (Eds.), Peptide Nucleic Acids: Protocols and Applications. Wymondham: Horizon Scientific Press (1999) 119-128.
66. Fiandaca, M.J., Hyldig-Nielsen, J.J. and Coull, J.M. PNA blocker probes enhance specificity in probe assays. In: P. Nielsen and M. Egholm (Eds.), Peptide Nucleic Acids: Protocols and Applications. Wymondham: Horizon Scientific Press (1999) 129-142.
67. Griffin, T.J., Tang, W. and Smith, L.M. MALDI-TOF mass spectrometric detection of PNA hybrids for genetic analysis. In: P. Nielsen and M. Egholm (Eds.), Peptide Nucleic Acids: Protocols and Applications. Wymondham: Horizon Scientific Press (1999) 143-154.
68. Wang, J. PNA biosensors for nucleic acid detection. In: P. Nielsen and M. Egholm (Eds.), Peptide Nucleic Acids: Protocols and Applications. Wymondham: Horizon Scientific Press (1999) 155-161.
69. Lacerra, G., Sierakowska, H., Carestia, C., Fucharoen, S., Summerton, J., Weller, D. and Kole, R. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA, 97 (2000) 9591-9596.
70. Deng, J., Hua, K., Lesser, S.S. and Harp, J.B. Activation of signal transducer and activator of transcription-3 during proliferative phases of 3T3-L1 adipogenesis. Endocrinology, 141 (2000) 2370-2376.
71. Lawn, R.M., Wade, D.P., Garvin, M.R., Wang, X., Schwartz, K., Porter, J.G., Seilhamer, J.J., Vaughan, A.M. and Oram, J.F. The Tangier disease gene product ABC 1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest., 104 (1999) R25-R31.
72. Giles, R.V., Spiller, D.G., Clark, R.E. and Tidd, D.M. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antis. Nucl. Acids Drug Dev., (Apr)9(2) (1999) 213-20.
73. Heasman, J., Kofron, M. and Wylie, C. Beta-catenin signaling activity dissected in the early Xenopus embryo: a novel antisense approach. Devel. Biol., 222 (2000) 124-134.
74. Nasevicius, A. and Ekker, S.C. Effective targeted gene 'knockdown' in zebrafish. Nat. Genetics, 26 (2000) 216-220.
75. Howard, E.W., Newman, L.A., Oleksyn, D.W., Angerer, R.C. and Angerer, L.M. SpKr1: a direct target of (beta)-catenin regulation required for endoderm differentiation in sea urchin embryos. Development, 128 (2001) 365-375.
76. Kos, R., Reedy, M.V., Johnson, R.L. and Erickson, C.A. The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. Development, 128 (2001) 1467-1479.
77. Draper, B.W., Morcos, P.A. and Kimmel, C.B. Inhibition of zebrafish fgf8 pre-mRNA splicing with Morpholino oligos: a quantifiable method for gene knockdown. Genesis, 30 (2001) 154-156.
78. Elbeik, T. et al. Quantitative and cost comparison of ultra-sensitive human immunodeficiency virus type 1 RNA viral load assays. J. Clin. Micro., 39 (2000) 1113-1120
79. Summerton, J.E., Weller, D.D. and Wages, J.M. Reagent and method for isolation and detection of selected nucleic acid sequences. US Patent; (2000), 6,060,246.
80. Tyler, B.M., McCormick, D.J., Hoshall, C.V., Douglas, C.L., Jansen, K., Lacy, B.W., Cusack, B. and Richelson, E. Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo. FEBS Lett. 421 (1998) 280-284.
81. Arora, V. and Iversen, P. Redirection of drug metabolism using antisense technology. Curr. Opin. Mol. Ther., 3 (2001) 249-257.
82. Brand, R.M. and Iversen, PL. Transdermal delivery of antisense compounds. Adv. Drug Develop. Rev., 44 (2000) 51-58.
83. Aurora, V. and Iversen, P.L. Antisense oligonucleotides targeted to the p53 gene modulate rat liver regeneration. Drug. Metab. Disp., 28 (2000) 131-138.
84. Qin, G., Taylor, M., Ning, Y.Y., Iversen, P. and Kobzik, L. In vivo evaluation of a morpholino antisense oligomer directed against TNF. Antis. Nucl. Acids Drug Develop., 10 (2000) 11-16.
85. Stein, C.A. and Cohen, J.S. Phosphorothioate oligodeoxynucleotide analogues. In: J. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Boca Raton: CRC Press (1989) 97-117.